OECD Health Working Papers

ISSN :
1815-2015 (online)
DOI :
10.1787/18152015
Hide / Show Abstract
This series is designed to make available to a wider readership health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language - English or French - with a summary in the other.
 

Pharmaceutical Pricing and Reimbursement Policies in Canada You or your institution have access to this content

Click to Access: 
    http://oecd.metastore.ingenta.com/content/5l4w393hfzq2.pdf
  • PDF
  • http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/pharmaceutical-pricing-and-reimbursement-policies-in-canada_346071162287
  • READ
Author(s):
Valérie Paris1, Elizabeth Docteur
Author Affiliations
  • 1: OECD, France

Publication Date
22 Dec 2006
Bibliographic information
No.:
24
Pages
91
DOI
10.1787/346071162287

Hide / Show Abstract

This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada’s achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada’s prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high...
Keywords:
Canada, pharmaceutical policy, pricing and reimbursement, pharmaceutical market
JEL Classification:
  • I11: Health, Education, and Welfare / Health / Analysis of Health Care Markets
  • I18: Health, Education, and Welfare / Health / Government Policy; Regulation; Public Health